A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

Hepatitis B Clinical Trial

Official title:

A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV™ in Adults With End-Stage Renal Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00498212
• Other study ID #: DV2-HBV-11
• Status: Terminated
• Phase: Phase 2
• Start date: July 2007
• Est. completion date: October 2008

Study information

• Verified date: March 2019
• Source: Dynavax Technologies Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out if a new investigational hepatitis B virus (HBV) vaccine, HEPLISAV™, is safe and effective for end-stage renal disease (ESRD) patients. Two dose levels will be studied: a single dose and a double dose. We expect both dose levels to safely immunize patients against HBV. The study will determine which dose does this best.

Description:

Infection with hepatitis B virus (HBV) is a major global health problem. Worldwide, it is estimated that 2 billion people have been infected previously and 350 million are chronically infected. While acute HBV infection is associated with significant illness, the risk of chronic infection is of great importance since 5-10% of infected adults will not clear the infection after the initial phase of the illness. About 25% of people who do not initially clear the infection will later develop chronic active hepatitis.

This study will evaluate the safety and immunogenicity of HEPLISAV™ when administered to adults who have end-stage renal disease (glomerular filtration rate [GFR] ≤ 45 mL/min). Once subjects have been consented, screened, and randomized to treatment, subjects will receive a total of three injections over a 24-week period, with follow-up visits at 28 and 50 weeks. Subjects will receive 1 of the following 2 regimens:

• HEPLISAV™ single dose at Day 0, 4 weeks (1 month) and 24 weeks (6 months)

• HEPLISAV™ double dose at Day 0, 4 weeks (1 month) and 24 weeks (6 months)

Safety and tolerability will be evaluated by occurrence of adverse events, periodic laboratory tests, vital signs, and local and systemic reactogenicity.

Immunogenicity will be evaluated by the proportion of subjects exhibiting a seroprotective immune response (anti-hepatitis B surface antigen antibodies [anti-HBsAg] ≥ 10 milli-international unit (mIU)/mL) at Weeks 4, 12, 24, 28 and 50.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 41
• Est. completion date: October 2008
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Willing and able to give written informed consent

• Have a glomerular filtration rate (GFR) = 45 mL/min

• Have an expectation of going on hemodialysis or are already on hemodialysis

• Is serum negative for hepatitis B virus (HBV) antibodies, hepatitis C virus (HCV), and human immunodeficiency virus (HIV)

• Have repeated resting blood pressure measurements = 165/105 mmHg

• Women of childbearing potential must be consistently using a highly effective method of birth control

Exclusion Criteria:

• Women who are pregnant, breastfeeding or planning a pregnancy

• Any previous HBV infection

• Previous vaccination (1 or more doses) with any HBV vaccine

• Any previous autoimmune diseases

• Have a diagnosis of chronic renal failure due to autoimmune disease

• Are at high risk for recent exposure to HBV, HCV or HIV

• Received any antibodies within 3 months prior to study entry

• Ever received an injection with DNA plasmids or oligonucleotides

• Received any vaccines within 4 weeks prior to study entry

• Received any other investigational medicinal agent within 4 weeks prior to study entry

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Kidney Diseases
• Kidney Failure, Chronic

Intervention

Biological:
• 1018 ISS-HBsAg-Single
Intramuscular (IM) injection at Day 0, Week 4 and Week 24
• 1018 ISS-HBsAg-Double
Intramuscular (IM) injection at Day 0, Week 4 and Week 24

Locations

Country	Name	City	State
Canada	QEII Health Sciences Centre	Halifax	Nova Scotia
Canada	SMBD - Jewish General Hospital	Montreal	Quebec
Canada	White Hills Medical Clinic	St Johns	Newfoundland and Labrador

Sponsors (1)

Lead Sponsor	Collaborator
Dynavax Technologies Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of adverse events and local and systemic reaction rates		28 weeks
Secondary	Portion of subjects who have a seroprotective immune response (anti-HBsAg = 10 mIU/ml)		50 weeks

External Links

•   Dynavax Webpage